Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

pulmonary tuberculosis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

pulmonary tuberculosis

MONDO:0006052

Also known as:lung TBlung tuberculosispulmonary TB

Find Clinical TrialsTrials

Overview

A bacterial infection that affects the lungs and is caused by Mycobacterium tuberculosis. Most patients with tuberculosis do not have symptoms (latent tuberculosis) and are not contagious. When signs and symptoms occur (active tuberculosis), patients become contagious. The signs and symptoms include chronic cough with blood-tinged sputum, night sweats, fever, fatigue, and weight loss.

Treatments1 FDA approved

Clinical Trials47 registered · 21 recruiting

Diagnosis

Biomarker and diagnostic research for pulmonary tuberculosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for pulmonary tuberculosis, including ETHAMBUTOL HYDROCHLORIDE (ETHAMBUTOL HYDROCHLORIDE, approved 1967). An additional 3 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

47 clinical trials registered, 21 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 2 PHASE4, 13 PHASE3, 15 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06199921](https://clinicaltrials.gov/study/NCT06199921)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 2:48 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of ETHAMBUTOL HYDROCHLORIDE for managing pulmonary tuberculosis?
→Are any of the 47 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole	Otsuka Pharmaceutical Company, Ltd	2007	—	Designated
Rifalazil	Rifalazil	PathoGenesis Corporation	1999	—	Designated
Priftin	Rifapentine	Hoechst Marion Roussel	1995	2005	Designated (drug approved for other indication)

Research Type	Count	% of Total
Disease patterns and progression	52	31%
Testing and diagnosis research	32	19%
Research summaries	29	17%
Patient case studies	24	14%
Laboratory research	14	8%
Clinical study results	10	6%
Other research	7	4%
New treatment approaches	2	1%

Kisho

pulmonary tuberculosis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability

pulmonary tuberculosis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability